Alberta Investment Management Corp Bei Gene, Ltd. Transaction History

Alberta Investment Management Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $1.05 Million - $1.32 Million	5,843 Added 214.26%	8,570 $1.54 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $486,224 - $727,509	2,727 New	2,727 $486,000
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $213,367 - $389,810	-1,700 Reduced 11.26%	13,399 $2.95 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $811,315 - $1.45 Million	6,699 Added 79.75%	15,099 $2.44 Million
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $891,574 - $1.64 Million	-6,085 Reduced 42.01%	8,400 $1.58 Million
Q4 2021 Feb 11, 2022	BUY	$248.56 - $389.34 $1.51 Million - $2.37 Million	6,085 Added 72.44%	14,485 $3.92 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $1.61 Million - $2.02 Million	5,500 Added 189.66%	8,400 $2.88 Million
Q1 2021 May 07, 2021	BUY	$260.64 - $382.12 $755,856 - $1.11 Million	2,900 New	2,900 $1.01 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

Stay updated on Alberta Investment Management Corp with notifications on news.